Results from A.P. Pharma’s APF530 Phase 3 trial on CINV

NewsGuard 100/100 Score

A.P. Pharma, Inc. (OTCBB: APPA.OB), a specialty pharmaceutical company, today announced that an abstract analyzing a subset of efficacy results from its Phase 3 trial of APF530 has been published in conjunction with the American Society of Clinical Oncology's (ASCO) 2012 Annual Meeting. APF530 is the Company's lead product candidate being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV).

The abstract concludes that continuous exposure to a 5-HT3 receptor antagonist, through the administration of an extended-release formulation such as APF530, results in better emetic (nausea and vomiting) control than administration of a standard, short-acting 5-HT3 receptor antagonist.

Source:

A.P. Pharma    

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Vitamin D receptor polymorphism found to influence COVID-19 severity